MX2020005952A - Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. - Google Patents

Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.

Info

Publication number
MX2020005952A
MX2020005952A MX2020005952A MX2020005952A MX2020005952A MX 2020005952 A MX2020005952 A MX 2020005952A MX 2020005952 A MX2020005952 A MX 2020005952A MX 2020005952 A MX2020005952 A MX 2020005952A MX 2020005952 A MX2020005952 A MX 2020005952A
Authority
MX
Mexico
Prior art keywords
mir101
treatment
mir128
seizure disorders
patient
Prior art date
Application number
MX2020005952A
Other languages
English (en)
Other versions
MX388998B (es
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of MX2020005952A publication Critical patent/MX2020005952A/es
Publication of MX388998B publication Critical patent/MX388998B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que aumenta el nivel de moléculas de microARN-101 en el cerebro de una paciente para usarse en el tratamiento de epilepsia en un paciente, en donde la composición incluye microARN-101, pri-miR101 o pre-miR101.
MX2020005952A 2017-12-06 2018-12-06 Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. MX388998B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762595255P 2017-12-06 2017-12-06
PCT/US2018/064158 WO2019113266A1 (en) 2017-12-06 2018-12-06 Use of mir101 or mir128 in the treatment of seizure disorders

Publications (2)

Publication Number Publication Date
MX2020005952A true MX2020005952A (es) 2022-01-03
MX388998B MX388998B (es) 2025-03-11

Family

ID=66658874

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020005952A MX388998B (es) 2017-12-06 2018-12-06 Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
MX2021011598A MX2021011598A (es) 2017-12-06 2020-07-13 Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021011598A MX2021011598A (es) 2017-12-06 2020-07-13 Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.

Country Status (10)

Country Link
US (2) US10870855B2 (es)
EP (1) EP3703820A4 (es)
JP (1) JP2021505619A (es)
KR (1) KR20200119782A (es)
CN (1) CN111417397A (es)
AU (1) AU2018378622A1 (es)
CA (1) CA3084985A1 (es)
IL (1) IL274838A (es)
MX (2) MX388998B (es)
WO (1) WO2019113266A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3084985A1 (en) 2017-12-06 2019-06-13 Ovid Therapeutics Inc. Use of mir101 or mir128 in the treatment of seizure disorders
BR112022002794A2 (pt) * 2019-08-15 2022-08-09 Childrens Hospital Philadelphia Terapia combinada de transgene e mirna derivado de íntron para tratamento de sca1
WO2025164317A1 (ja) * 2024-01-31 2025-08-07 国立大学法人群馬大学 改良型ミクログリア標的ａａｖベクター

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3499437A (en) 1967-03-10 1970-03-10 Ultrasonic Systems Method and apparatus for treatment of organic structures and systems thereof with ultrasonic energy
US4303636A (en) 1974-08-20 1981-12-01 Gordon Robert T Cancer treatment
US4315514A (en) 1980-05-08 1982-02-16 William Drewes Method and apparatus for selective cell destruction
US4923437A (en) 1986-07-18 1990-05-08 Gordon Robert T Process for applying a localized magnetic or electric field
US5059415A (en) 1989-02-21 1991-10-22 The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon Health Method for diagnostically imaging lesions in the brain inside a blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5438989A (en) 1990-08-10 1995-08-08 Hochman; Darryl Solid tumor, cortical function, and nerve tissue imaging methods and device
US5465718A (en) 1990-08-10 1995-11-14 Hochman; Daryl Solid tumor, cortical function, and nerve tissue imaging methods and device
DE4227800C2 (de) 1991-08-21 1996-12-19 Toshiba Kawasaki Kk Thrombuslösende Behandlungsvorrichtung
US5291890A (en) 1991-08-29 1994-03-08 General Electric Company Magnetic resonance surgery using heat waves produced with focussed ultrasound
US5524620A (en) 1991-11-12 1996-06-11 November Technologies Ltd. Ablation of blood thrombi by means of acoustic energy
JP3325300B2 (ja) 1992-02-28 2002-09-17 株式会社東芝 超音波治療装置
US5368032A (en) 1993-11-09 1994-11-29 General Electric Company Manually positioned focussed energy system guided by medical imaging
US5526814A (en) 1993-11-09 1996-06-18 General Electric Company Automatically positioned focussed energy system guided by medical imaging
US5443068A (en) 1994-09-26 1995-08-22 General Electric Company Mechanical positioner for magnetic resonance guided ultrasound therapy
US5752515A (en) 1996-08-21 1998-05-19 Brigham & Women's Hospital Methods and apparatus for image-guided ultrasound delivery of compounds through the blood-brain barrier
EP1937151A4 (en) 2005-09-19 2011-07-06 Univ Columbia Systems and methods for opening of the blood-brain barrier of a subject using ultrasound
EP2068925A4 (en) * 2007-05-07 2011-08-31 Medimmune Llc ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
US9163261B2 (en) * 2010-02-22 2015-10-20 Koteswara Rao KOLLIPARA Adeno-associated virus 2/8—micro RNA-101 therapy for liver cancer
GB201103062D0 (en) * 2011-02-22 2011-04-06 Isis Innovation Method
GB201223244D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Gmbh Micrornas as therapeutics and biomarkers for epilepsy
CN107207597A (zh) * 2014-11-06 2017-09-26 儿研所儿童医学中心 用于癌症和自身免疫疾病的免疫疗法
TN2017000354A1 (en) * 2015-02-10 2019-01-16 Genzyme Corp VARIANT RNAi
WO2017024111A1 (en) * 2015-08-04 2017-02-09 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
EP3413925A1 (en) * 2016-02-12 2018-12-19 Combigene AB Vector
CA3056410A1 (en) * 2017-03-15 2018-09-20 Ovid Therapeutics, Inc. Use of designer receptors exclusively activated by designer drugs in the treatment of seizure disorders
CA3084985A1 (en) 2017-12-06 2019-06-13 Ovid Therapeutics Inc. Use of mir101 or mir128 in the treatment of seizure disorders

Also Published As

Publication number Publication date
WO2019113266A1 (en) 2019-06-13
CA3084985A1 (en) 2019-06-13
EP3703820A1 (en) 2020-09-09
AU2018378622A1 (en) 2020-05-28
JP2021505619A (ja) 2021-02-18
US20210095292A1 (en) 2021-04-01
US20190169619A1 (en) 2019-06-06
US10870855B2 (en) 2020-12-22
EP3703820A4 (en) 2020-12-09
MX2021011598A (es) 2021-10-13
MX388998B (es) 2025-03-11
IL274838A (en) 2020-07-30
CN111417397A (zh) 2020-07-14
KR20200119782A (ko) 2020-10-20
US11761006B2 (en) 2023-09-19

Similar Documents

Publication Publication Date Title
UY36550A (es) Oligómeros antisentido de tau y sus usos
SV2017005420A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CL2017001046A1 (es) Inhibidoes del bromodominio
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
UY36071A (es) Compuesto de ciclopropanamina y sus usos
MX391725B (es) Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
CO2017005034A2 (es) Tratamiento de convulsiones con fosfatasa alcalina recombinante
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
MX381069B (es) Profármacos de carbidopa y l-dopa y métodos de uso.
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
CL2018003451A1 (es) Moduladores del receptor adrenergico beta-3 que sirve para el tratamiento o la prevensión de desordenes relacionados.
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
MX2016005446A (es) Intervenciones a base de angiopoyetina para tratar la malaria cerebral.
CL2016002615A1 (es) Heterociclil-sulfonas sustituidas con heteroarilo y su uso contra el dolor, accidente cerebrovascular, transtornos anímicos, epilepsia, esquizofrenia y trastornos neurodegenerativos.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MX383323B (es) Grelina para uso en el tratamiento de lesión del cerebro traumática leve.
BR112017025263A2 (pt) método para o tratamento de doença neurológica
MX2020005952A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.